<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">33002998</PMID>
      <DateCompleted>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>28</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2021</Year>
        <Month>07</Month>
        <Day>28</Day>
      </DateRevised>
      <Article PubModel="Print">
        <Journal>
          <ISSN IssnType="Electronic">1538-6899</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>26</Volume>
            <Issue>5</Issue>
            <PubDate>
              <Year>2020</Year>
              <Month>Oct</Month>
            </PubDate>
          </JournalIssue>
          <Title>Continuum (Minneapolis, Minn.)</Title>
          <ISOAbbreviation>Continuum (Minneap Minn)</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Guillain-Barré Syndrome.</ArticleTitle>
        <Pagination>
          <StartPage>1184</StartPage>
          <EndPage>1204</EndPage>
          <MedlinePgn>1184-1204</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1212/CON.0000000000000929</ELocationID>
        <Abstract>
          <AbstractText Label="PURPOSE OF REVIEW">This article reviews the clinical features, diagnosis and differential diagnosis, prognosis, pathogenesis, and current and upcoming treatments of Guillain-Barré syndrome (GBS).</AbstractText>
          <AbstractText Label="RECENT FINDINGS">GBS is an acute inflammatory neuropathic illness with striking clinical manifestations and significant morbidity. A substantial proportion of patients with GBS do not respond to current immunomodulatory therapies (ie, plasma exchange and IV immunoglobulin [IVIg]), highlighting the need for new therapies. Prognostic models that can accurately predict functional recovery and the need for artificial ventilation have emerged. These models are practical, and online calculators are available for clinical use, facilitating early recognition of patients with poor outcome and the opportunity to personalize management decisions. Clinical and experimental studies have identified innate immune effectors (complement, macrophage lineage cells, and activating Fcγ receptors) as important mediators of inflammatory nerve injury. Two complement inhibitors are undergoing clinical testing for efficacy in GBS.</AbstractText>
          <AbstractText Label="SUMMARY">GBS is the most common cause of acute flaccid paralysis in the United States and worldwide. New treatments for GBS have not emerged since the 1990s. Our understanding of the pathogenesis of this disorder has progressed, particularly over the past decade; as a result, new therapeutic agents targeting different components of the complement cascade are at advanced stages of clinical development.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Sheikh</LastName>
            <ForeName>Kazim A</ForeName>
            <Initials>KA</Initials>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <GrantList CompleteYN="Y">
          <Grant>
            <GrantID>R21 NS107961</GrantID>
            <Acronym>NS</Acronym>
            <Agency>NINDS NIH HHS</Agency>
            <Country>United States</Country>
          </Grant>
        </GrantList>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType>
          <PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Continuum (Minneap Minn)</MedlineTA>
        <NlmUniqueID>9509333</NlmUniqueID>
        <ISSNLinking>1080-2371</ISSNLinking>
      </MedlineJournalInfo>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020275" MajorTopicYN="N">Guillain-Barre Syndrome</DescriptorName>
          <QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName>
          <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
          <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>1</Day>
          <Hour>20</Hour>
          <Minute>22</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>10</Month>
          <Day>2</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2021</Year>
          <Month>7</Month>
          <Day>29</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">33002998</ArticleId>
        <ArticleId IdType="doi">10.1212/CON.0000000000000929</ArticleId>
        <ArticleId IdType="pii">00132979-202010000-00006</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Sejvar JJ, Baughman AL, Wise M, Morgan OW. Population incidence of Guillain-Barré syndrome: a systematic review and meta-analysis. Neuroepidemiology 2011;36(2):123–133. doi:10.1159/000324710.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1159/000324710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Cornblath DR. Guillain-Barré syndrome. Lancet 2005;366(9497):1653–1666.</Citation>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Arnason BG, Karp HR, McFarlin DE. Criteria for diagnosis of Guillain-Barré syndrome. Ann Neurol 1978;3:565–566. doi:10.1016/S0140-6736(05)67665-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(05)67665-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27(suppl):S21–S24. doi:10.1002/ana.410270707.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410270707</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sejvar JJ, Kohl KS, Gidudu J, et al. Guillain-Barré syndrome and Fisher syndrome: case definitions and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2011;29(3):599–612. doi:10.1016/j.vaccine.2010.06.003.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.vaccine.2010.06.003</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Lingsma HF, Ruts L, et al. Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 2010;67(6):781–787. doi:10.1002/ana.21976.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21976</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Yuki N, Kokobun N, Kuwabara S, et al. Guillain-Barré syndrome associated with normal or exaggerated tendon reflexes. J Neurol 2012;259(6):1181–1190. doi:10.1007/s00415-011-6330-4.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00415-011-6330-4</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Doets AY, Verboon C, van den Berg B, et al. Regional variation of Guillain-Barré syndrome. Brain 2018;141(10):2866–2877. doi:10.1093/brain/awy232.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awy232</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feasby TE, Gilbert JJ, Brown WF, et al. An acute axonal form of Guillain-Barré polyneuropathy. Brain 1986;109(pt 6):1115–1126. doi:10.1093/brain/109.6.1115.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/109.6.1115</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Yuki N. Sensory Guillain-Barré syndrome and related disorders: an attempt at systematization. Muscle Nerve 2012;45(4):464–470. doi:10.1002/mus.22298.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/mus.22298</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K, Bos-Eyssen ME, Blomkwist-Markens PH, van Doorn PA. Recurrences, vaccinations and long-term symptoms in GBS and CIDP. J Peripher Nerv Syst 2009;14(4):310–315. doi:10.1111/j.1529-8027.2009.00243.x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1111/j.1529-8027.2009.00243.x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>van den Berg B, Bunschoten C, van Doorn PA, Jacobs BC. Mortality in Guillain-Barré syndrome. Neurology 2013;80(18):1650–1654. doi:10.1212/WNL.0b013e3182904fcc.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182904fcc</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hadden RD, Cornblath DR, Hughes RA, et al. Electrophysiological classification of Guillain-Barré syndrome: clinical associations and outcome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Ann Neurol 1998;44(5):780–788. doi:10.1002/ana.410440512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410440512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Uncini A, Susuki K, Yuki N. Nodo-paranodopathy: beyond the demyelinating and axonal classification in anti-ganglioside antibody-mediated neuropathies. Clin Neurophysiol 2013;124(10):1928–1934. doi:10.1016/j.clinph.2013.03.025.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.clinph.2013.03.025</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Fokke C, van den Berg B, Drenthen J, et al. Diagnosis of Guillain-Barré syndrome and validation of Brighton criteria. Brain 2014;137(pt 1):33–43. doi:10.1093/brain/awt285.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awt285</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Haymaker WE, Kernohan JW. The Landry-Guillain-Barré syndrome: a clinicopathologic report of 50 fatal cases and a critique of the literature. Medicine (Baltimore);28(1):59–141.</Citation>
        </Reference>
        <Reference>
          <Citation>Loffel NB, Rossi LN, Mumenthaler M, et al. The Landry-Guillain-Barré syndrome. Complications, prognosis and natural history in 123 cases. J Neurol Sci 1977;33(1-2):71–79. doi:10.1016/0022-510x(77)90183-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/0022-510x(77)90183-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ogawara K, Kuwabara S, Mori M, et al. Axonal Guillain-Barré syndrome: relation to anti-ganglioside antibodies and Campylobacter jejuni infection in Japan. Ann Neurol 2000;48(4):624–631. doi:10.1002/1531-8249(200010)48:43.3.CO;2-F.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(200010)48:43.3.CO;2-F</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ho TW, Willison HJ, Nachamkin I, et al. Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barré syndrome. Ann Neurol 1999;45(2):168–173. doi:10.1002/1531-8249(199902)45:2&lt;168::aid-ana6&gt;3.0.co;2-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/1531-8249(199902)45:2&lt;168::aid-ana6&gt;3.0.co;2-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Willison HJ, Yuki N. Peripheral neuropathies and anti-glycolipid antibodies. Brain 2002;125(pt 12):2591–1625. doi:10.1093/brain/awf272.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awf272</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goodfellow JA, Willison HJ. Antiganglioside, antiganglioside-complex, and antiglycolipid-complex antibodies in immune-mediated neuropathies. Curr Opin Neurol 2016;29(5):572–580. doi:10.1097/WCO.0000000000000361.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/WCO.0000000000000361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Newsom-Davis JM, Perkin GD, Pierce JM. Controlled trial prednisolone in acute polyneuropathy. Lancet 1978;2(8093):750–753. doi:10.1016/s0140-6736(78)92644-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0140-6736(78)92644-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>IGOS GBS Prognosis Tool. gbstools.erasmusmc.nl. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Walgaard C, Lingsma HF, Ruts L, et al. Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 2011;76(11):968–975. doi:10.1212/WNL.0b013e3182104407.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0b013e3182104407</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic polyneuritis. Its role in pathogenesis. Medicine (Baltimore) 1969;48(3):173–215. doi:10.1097/00005792-196905000-00001.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/00005792-196905000-00001</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafer-Macko C, Sheikh KA, Li CY, et al. Immune attack on the Schwann cell surface in acute inflammatory demyelinating polyneuropathy. Ann Neurol 1996;39(5):625–635. doi:10.1002/ana.410390512.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410390512</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Griffin JW, Li CY, Ho TW, et al. Guillain-Barré syndrome in northern China; the spectrum of neuropathological changes in clinically defined cases. Brain 1995;118(pt 3):577–595. doi:10.1093/brain/118.3.577.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/118.3.577</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hafer-Macko C, Hsieh ST, Li CY, et al. Acute motor axonal neuropathy: an antibody-mediated attack on axolemma. Ann Neurol 1996;40(4):635–644. doi:10.1002/ana.410400414.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410400414</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Bogdanova N, Gao T, et al. Fcγ receptor-mediated inflammation inhibits axon regeneration. PLoS One 2014;9(2):e88703. doi:10.1371/journal.pone.0088703.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0088703</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chi LJ, Wang HB, Zhang Y, Wang WZ. Abnormality of circulating CD4(+)CD25(+) regulatory T cell in patients with Guillain-Barré syndrome. J Neuroimmunol 2007;192(1–2):206–214. doi:10.1016/j.jneuroim.2007.09.034.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.jneuroim.2007.09.034</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maddur MS, Rabin M, Hegde P, et al. Intravenous immunoglobulin exerts reciprocal regulation of Th1/Th17 cells and regulatory T cells in Guillain-Barré syndrome patients. Immunol Res 2014;60(2–3):320–329. doi:10.1007/s12026-014-8580-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s12026-014-8580-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Moran AP, Prendergast MM, Hogan EL. Sialosyl-galactose: a common denominator of Guillain-Barré and related disorders?J Neurol Sci 2002;196(1–2):1–7. doi:10.1016/s0022-510x(02)00036-9.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/s0022-510x(02)00036-9</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Tam CC, Rodrigues LC, Petersen I, et al. Incidence of Guillain-Barré syndrome among patients with Campylobacter infection: a general practice research database study. J Infect Dis 2006;194(1):95–97. doi:10.1086/504294.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1086/504294</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Cao-Lormeau VM, Blake A, Mons S, et al. Guillain-Barré syndrome outbreak associated with Zika virus infection in French Polynesia: a case-control study. Lancet 2016;387(10027):1531–1539. doi:10.1016/S0140-6736(16)00562-6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(16)00562-6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Parra B, Lizarazo J, Jiménez-Arango JA, et al. Guillain-Barré syndrome associated with Zika virus infection in Colombia. N Engl J Med 2016;375(16):1513–1523. doi:10.1056/NEJMoa1605564.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMoa1605564</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhao H, Shen D, Zhou H, et al. Guillain-Barré syndrome associated with SARS-CoV-2 infection: causality or coincidence?Lancet Neurol 2020;19(5):383–384. doi:10.1016/S1474-4422(20)30109-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(20)30109-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Goscano G, Palmerini F, Ravaglia S, et al. Guillain-Barré syndrome associated with SARS-CoV-2. N Engl J Med 2020;382:2574–2576. doi:10.1056/NEJMc2009191.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1056/NEJMc2009191</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gutiérrez-Ortiz C, Méndez A, Rodrigo-Rey S, et al. Miller Fisher syndrome and polyneuritis cranialis in COVID-19. Neurology 2020. Published online April 17, 2020. doi:10.1212/WNL.0000000000009619.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000009619</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Arnason BG, Asbury AK. Idiopathic polyneuritis after surgery. Arch Neurol 1968;18(5):500–507. doi:10.1001/archneur.1968.00470350058005.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1001/archneur.1968.00470350058005</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Rudant J, Dupont A, Mikaeloff Y, et al. Surgery and risk of Guillain-Barré syndrome: a French nationwide epidemiologic study. Neurology 2018;91(13):e1220–e1227. doi:10.1212/WNL.0000000000006246.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.0000000000006246</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lehmann HC, Hartung HP, Kieseier BC, Hughes RA. Guillain-Barré syndrome after exposure to influenza virus. Lancet Infect Dis 2010;10(9):643–651. doi:10.1016/S1473-3099(10)70140-7.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1473-3099(10)70140-7</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Halstead SK, Zitman FM, Humphreys PD, et al. Eculizumab prevents anti-ganglioside antibody-mediated neuropathy in a murine model. Brain 2008;131(pt 5):1197–1208. doi:10.1093/brain/awm316.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1093/brain/awm316</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He L, Zhang G, Liu W, et al. Anti-ganglioside antibodies induce nodal and axonal injury via Fcγ receptor-mediated inflammation. J Neurosci 2015;35(17):6770–6785. doi:10.1523/JNEUROSCI.4926-14.2015.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1523/JNEUROSCI.4926-14.2015</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Bogdanova N, Gao T, Sheikh KA. Elimination of activating Fcγ receptors in spontaneous autoimmune peripheral polyneuropathy model protects from neuropathic disease. PLoS One 2019;14(8):e0220250. doi:10.1371/journal.pone.0220250.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1371/journal.pone.0220250</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hughes RA, Swan AV, van Doorn PA. Intravenous immunoglobulin for Guillain-Barré syndrome. Cochrane Database Syst Rev 2014;19(9):CD002063. doi:10.1002/14651858.CD002063.pub6.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/14651858.CD002063.pub6</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>The Guillain-Barré Syndrome Study Group. Plasmapheresis and acute Guillain-Barré syndrome. Neurology 1985;35(8):1096–1104. doi:10.1212/WNL.35.8.1096.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1212/WNL.35.8.1096</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Efficiency of plasma exchange in Guillain-Barré syndrome: role of replacement fluids. French Cooperative Group on Plasma Exchange in Guillain-Barré syndrome. Ann Neurol 1987;22(6):753–761. doi:10.1002/ana.410220612.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.410220612</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Randomised trial of plasma exchange, intravenous immunoglobulin, and combined treatments in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet 1997;349(9047):225–230. doi:10.1016/S0140-6736(96)09095-2.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S0140-6736(96)09095-2</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Oczko-Walker M, Manousakis G, Wang S, et al. Plasma exchange after initial intravenous immunoglobulin treatment in Guillain-Barré syndrome: critical reassessment of effectiveness and cost-efficiency. J Clin Neuromuscul Dis 2010;12(2):55–61. doi:10.1097/CND.0b013e3181f3dbbf.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1097/CND.0b013e3181f3dbbf</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Verboon C, van den Berg B, Cornblath DR, et al. Original research: second IVIg course in Guillain-Barré syndrome with poor prognosis: the non-randomised ISID study. J Neurol Neurosurg Psychiatry 2020;91(2):113–121. doi:10.1136/jnnp-2019-321496.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp-2019-321496</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuitwaard K, de Gelder J, Tio-Gillen AP, et al. Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 2009;66(5):597–603. doi:10.1002/ana.21737.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1002/ana.21737</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Visser LH, van der Meché FG, Meulstee J, van Doorn PA. Risk factors for treatment related clinical fluctuations in Guillain-Barré syndrome. Dutch Guillain-Barré study group. J Neurol Neurosurg Psychiatry 1998;64(2):242–244. doi:10.1136/jnnp.64.2.242.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1136/jnnp.64.2.242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Korinthenberg R, Schessl J, Kirschner J, Mönting JS. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Pediatrics 2005;116(1):8–14. doi:10.1542/peds.2004-1324.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1542/peds.2004-1324</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>El-Bayoumi MA, El-Refaey AM, Abdelkader AM, et al. Comparison of intravenous immunoglobulin and plasma exchange in treatment of mechanically ventilated children with Guillain Barré syndrome: a randomized study. Crit Care 2011;15(4):R164. doi:10.1186/cc10305.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1186/cc10305</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. JET-GBS—Japanese Eculizumab Trial for GBS. clinicaltrials.gov/ct2/show/NCT02493725?cond=02493725&amp;draw=1&amp;rank=1. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Misawa S, Kuwabara S, Sato Y, et al. Safety and efficacy of eculizumab in Guillain-Barré syndrome: a multicentre, double-blind, randomised phase 2 trial. Lancet Neurol 2018;17(6):519–529. doi:10.1016/S1474-4422(18)30114-5.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/S1474-4422(18)30114-5</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Lansita JA, Mease KM, Qiu H, et al. Nonclinical development of ANX005: a humanized anti-C1q antibody for treatment of autoimmune and neurodegenerative diseases. Int J Toxicol 2017;36(6):449–462. doi:10.1177/1091581817740873.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1177/1091581817740873</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. A Clinical Study of ANX005 and IVIG in Subjects With Guillain Barré Syndrome (GBS). clinicaltrials.gov/ct2/show/NCT04035135?cond=04035135&amp;draw=2&amp;rank=1. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang G, Lin J, Ghauri S, Sheikh KA. Modulation of IgG-FcRn interactions to overcome antibody-mediated inhibition of nerve regeneration. Acta Neuropathol 2017;134(2):321–324. doi:10.1007/s00401-017-1730-x.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1007/s00401-017-1730-x</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy. clinicaltrials.gov/ct2/show/NCT04051944?cond=NCT04051944&amp;draw=2&amp;rank=1. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>ClinicalTrials.gov. Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenia Purpura (ITP) Patients. clinicaltrials.gov/ct2/show/NCT03866577?cond=NCT03866577&amp;draw=2&amp;rank=1. Accessed August 3, 2020.</Citation>
        </Reference>
        <Reference>
          <Citation>Washburn N, Schwab I, Ortiz D, et al. Controlled tetra-Fc sialylation of IVIg results in a drug candidate with consistent enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A 2015;112(11):E1297–E1306. doi:10.1073/pnas.1422481112.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1073/pnas.1422481112</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang G, Massaad CA, Gao T, et al. Sialylated intravenous immunoglobulin suppress anti-ganglioside antibody mediated nerve injury. Exp Neurol 2016;282:49–55. doi:10.1016/j.expneurol.2016.05.020.</Citation>
          <ArticleIdList>
            <ArticleId IdType="doi">10.1016/j.expneurol.2016.05.020</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
